Cannabinoid-based Gum

Testing stages of Cannabinoid-based gum to treat spasticity in MS - follow online

Axim Biotechnologies, a cannabinoid-based product developer, has released a product pipeline chart highlighting development timelines for its cannabinoid-based therapeutics, including those for people with MS.

The chart illustrates the stage each drug is in, from preclinical testing to, eventually, applications for regulatory approval, the diseases and their symptoms that each is meant to treat, and an anticipated market introduction date.

Among the products spotlighted is the first patented cannabinoid controlled-release chewing gum, Med-Chew 1401, to treat pain and spasticity in MS patients. Axim anticipates starting a proof-of-concept Phase 2a clinical trial of the gum next year, and its possible market release in 2018 or 2019. You can read the full story here

Minister for Health Simon Harris recently announced a review of Ireland’s policies relating to medicinal cannabis. You can read the full story and MS Ireland’s response

Read MS Ireland’s position paper on cannabis-based medicinal products